| scholarly article | Q13442814 |
| P50 | author | Agostino Tafuri | Q85907041 |
| P2093 | author name string | Massimo Libra | |
| James A McCubrey | |||
| Lucio Cocco | |||
| Saverio Candido | |||
| Alberto M Martelli | |||
| Linda S Steelman | |||
| Stephen L Abrams | |||
| Peter P Ruvolo | |||
| Vivian R Ruvolo | |||
| Giovanni Ligresti | |||
| Stefano Ratti | |||
| P2860 | cites work | Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients | Q38793389 |
| JNK pathway inhibition selectively primes pancreatic cancer stem cells to TRAIL-induced apoptosis without affecting the physiology of normal tissue resident stem cells | Q38797029 | ||
| MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma. | Q38803437 | ||
| Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells. | Q38820303 | ||
| The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer | Q38858580 | ||
| The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells | Q38871688 | ||
| PTEN inhibitors: an evaluation of current compounds. | Q38935528 | ||
| Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes | Q38936206 | ||
| Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation | Q38949674 | ||
| Reversal of phenotypes of cellular senescence by pan-mTOR inhibition. | Q38964715 | ||
| Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. | Q39119297 | ||
| p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. | Q39237016 | ||
| Molecular mechanisms of sorafenib action in liver cancer cells. | Q39313526 | ||
| Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a | Q39328413 | ||
| Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. | Q39344848 | ||
| Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs | Q39370677 | ||
| Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia | Q24313505 | ||
| Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies | Q26750639 | ||
| The PTEN tumor suppressor gene and its role in lymphoma pathogenesis | Q26776527 | ||
| The 26S proteasome is a multifaceted target for anti-cancer therapies | Q26795764 | ||
| Targeted therapy for hepatocellular carcinoma: novel agents on the horizon | Q27002288 | ||
| Mutant HRAS as novel target for MEK and mTOR inhibitors | Q27853238 | ||
| Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade | Q27853295 | ||
| The role of p53 in cancer drug resistance and targeted chemotherapy | Q28072553 | ||
| Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells | Q28072650 | ||
| Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis | Q28237462 | ||
| Human immunodeficiency virus 1 envelope glycoprotein complex-induced apoptosis involves mammalian target of rapamycin/FKBP12-rapamycin-associated protein-mediated p53 phosphorylation | Q28361869 | ||
| Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway | Q28468627 | ||
| The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer | Q28468629 | ||
| PI3Kα inhibition reduces obesity in mice | Q28818545 | ||
| miR-503-5p confers drug resistance by targeting PUMA in colorectal carcinoma | Q33591648 | ||
| PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines | Q33618630 | ||
| Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma | Q33618658 | ||
| Combined MEK and Pi3'-kinase inhibition reveals synergy in targeting thyroid cancer in vitro and in vivo. | Q33648582 | ||
| Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5 | Q33709955 | ||
| Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma | Q33728138 | ||
| Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. | Q33823577 | ||
| Antineoplastic effects of CPPTL via the ROS/JNK pathway in acute myeloid leukemia | Q33889046 | ||
| Antiproliferative effect of ZSTK474 alone or in combination with chemotherapeutic drugs on HL60 and HL60/ADR cells | Q33889083 | ||
| HIV-1 Tat inhibits EAAT-2 through AEG-1 upregulation in models of HIV-associated neurocognitive disorder | Q33889434 | ||
| Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway. | Q33926909 | ||
| Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope | Q34090039 | ||
| Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. | Q34775779 | ||
| The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo | Q35122947 | ||
| Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells | Q35176419 | ||
| Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2 | Q35273305 | ||
| Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies | Q39383689 | ||
| Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. | Q39590044 | ||
| Targeting the cancer initiating cell: The Achilles’ heel of cancer | Q39638171 | ||
| Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. | Q39650704 | ||
| Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. | Q39653305 | ||
| Yin Yang 1 overexpression in diffuse large B-cell lymphoma is associated with B-cell transformation and tumor progression | Q39750949 | ||
| Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells. | Q40006122 | ||
| Akt inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cells | Q40015639 | ||
| Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. | Q40024347 | ||
| Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma | Q40060996 | ||
| Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. | Q40154931 | ||
| A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. | Q40160733 | ||
| Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts | Q40184405 | ||
| Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells | Q40355264 | ||
| Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway | Q40387396 | ||
| Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. | Q40490617 | ||
| Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. | Q40780780 | ||
| A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells. | Q40896676 | ||
| Fortifying p53 - beyond Mdm2 inhibitors | Q41548881 | ||
| Growth-promoting effects of insulin-like growth factor-1 (IGF-1) on hematopoietic cells: overexpression of introduced IGF-1 receptor abrogates interleukin-3 dependency of murine factor-dependent cells by a ligand-dependent mechanism | Q41669915 | ||
| Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer | Q41906245 | ||
| The puzzling interplay between p53 and Sp1. | Q42200102 | ||
| SHIP prevents metastasis. | Q42433801 | ||
| Targeting mutant p53 for cancer therapy | Q42433820 | ||
| Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia | Q42440865 | ||
| Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients | Q42541266 | ||
| TOR-inhibitors as gero-suppressors | Q43089284 | ||
| Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells | Q43122718 | ||
| Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms | Q43143677 | ||
| Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance | Q44358965 | ||
| Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia. | Q44498168 | ||
| Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. | Q45983199 | ||
| Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance | Q46441674 | ||
| Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin | Q46450365 | ||
| The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism | Q46666883 | ||
| Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors | Q73875877 | ||
| The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage: implications for therapy of drug resistant | Q83603505 | ||
| PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects | Q35552005 | ||
| Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells | Q35556981 | ||
| Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy | Q35640228 | ||
| Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells | Q35640301 | ||
| PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. | Q35833018 | ||
| Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay. | Q35889109 | ||
| PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia | Q35955221 | ||
| A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells | Q36140634 | ||
| Insulin/IGF1-PI3K-dependent nucleolar localization of a glycolytic enzyme--phosphoglycerate mutase 2, is necessary for proper structure of nucleolus and RNA synthesis | Q36232013 | ||
| Epithelial to mesenchymal transition is associated with rapamycin resistance | Q36260570 | ||
| A novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition | Q36411101 | ||
| Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells | Q36544358 | ||
| Proteolytic systems and AMP-activated protein kinase are critical targets of acute myeloid leukemia therapeutic approaches. | Q36544596 | ||
| Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia | Q36544778 | ||
| Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma | Q36557486 | ||
| Cetuximab enhanced the efficacy of chemotherapeutic agent in ABCB1/P-glycoprotein-overexpressing cancer cells | Q36562186 | ||
| RETRACTED ARTICLE: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex | Q36706340 | ||
| The miR27b-CCNG1-P53-miR-508-5p axis regulates multidrug resistance of gastric cancer | Q36729463 | ||
| Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. | Q36738818 | ||
| TLE4 promotes colorectal cancer progression through activation of JNK/c-Jun signaling pathway | Q36771972 | ||
| Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside | Q36907296 | ||
| Systematic proteome analysis identifies transcription factor YY1 as a direct target of miR-34a | Q36921032 | ||
| A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia | Q36926129 | ||
| Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein | Q36962430 | ||
| Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy | Q36973814 | ||
| Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells | Q37001645 | ||
| Reduced SOD2 expression is associated with mortality of hepatocellular carcinoma patients in a mutant p53-dependent manner | Q37062439 | ||
| Preclinical validation of a novel compound targeting p70S6 kinase in breast cancer. | Q37062488 | ||
| Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs | Q37192602 | ||
| The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy | Q37192611 | ||
| Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy | Q37192616 | ||
| Activation of anaphase-promoting complex by p53 induces a state of dormancy in cancer cells against chemotherapeutic stress | Q37295389 | ||
| The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy | Q37299276 | ||
| BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth | Q37317385 | ||
| A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells | Q37324522 | ||
| Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. | Q37331720 | ||
| Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia | Q37331742 | ||
| Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway | Q37360025 | ||
| Hepatocyte SLAMF3 reduced specifically the multidrugs resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugs. | Q37362692 | ||
| Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells | Q37376388 | ||
| Enrichment of hematopoietic precursor cells and cloning of multipotential B-lymphocyte precursors | Q37554117 | ||
| Targeting cancer stem cells with p53 modulators. | Q37564349 | ||
| Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells | Q37687154 | ||
| An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells | Q37687374 | ||
| Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells | Q37687457 | ||
| Targeting p53-deficient chronic lymphocytic leukemia cells in vitro and in vivo by ROS-mediated mechanism | Q37687622 | ||
| Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells | Q37692593 | ||
| The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer | Q37702100 | ||
| Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications. | Q37702626 | ||
| Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma. | Q37706739 | ||
| Cordycepin induces apoptosis by caveolin-1-mediated JNK regulation of Foxo3a in human lung adenocarcinoma. | Q37707076 | ||
| Vitexin suppresses autophagy to induce apoptosis in hepatocellular carcinoma via activation of the JNK signaling pathway | Q37708976 | ||
| MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma | Q37709001 | ||
| Kallikrein-related peptidase 6 induces chemotherapeutic resistance by attenuating auranofin-induced cell death through activation of autophagy in gastric cancer. | Q37709144 | ||
| The p53/miR-34 axis in development and disease | Q38210767 | ||
| Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis | Q38276802 | ||
| PLC and PI3K/Akt/mTOR signalling in disease and cancer | Q38284551 | ||
| Combined effects of aberrant MEK1 activity and BCL2 overexpression on relieving the cytokine dependency of human and murine hematopoietic cells. | Q38311147 | ||
| Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer | Q38311480 | ||
| New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463 | Q38432775 | ||
| Class I PI 3-kinases: Function and evolution | Q38544504 | ||
| Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells | Q38563570 | ||
| Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF-kappa-B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cells | Q38622611 | ||
| Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo | Q38707201 | ||
| Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy | Q38762743 | ||
| P433 | issue | 44 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| drug resistance | Q12147416 | ||
| apoptotic process | Q14599311 | ||
| P304 | page(s) | 76525-76557 | |
| P577 | publication date | 2017-08-24 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells | |
| P478 | volume | 8 |
| Q49882954 | Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression | cites work | P2860 |
Search more.